MiniMed Group, Inc.

MiniMed Group, Inc.

Overview

MiniMed Group, Inc. is a global medical technology company focused on diabetes management. The company designs, develops, manufactures, and markets an integrated Smart Dosing ecosystem that combines insulin delivery (tubed pumps and patch pumps), continuous glucose monitoring (CGMs), dosing algorithms, consumables, software, and support services.

Products and pipeline

• Core offering: an end-to-end diabetes management platform that integrates hardware (pumps, CGMs, sensors, infusion sets, reservoirs), firmware/software (dosing algorithms, apps, data analytics), and clinical support tools (CareLink, CareLink Connect, MiniMed IQ, My Insights).
• Product families:
  • Automated Insulin Delivery (AID) systems, led by MiniMed 780G and its successors (770G, 740G, 720G, 630G lineage) with the SmartGuard dosing algorithm and Meal Detection technology.
  • Smart Multiple Daily Injection (Smart MDI) systems, including InPen and the evolving MiniMed Go smart insulin pen with integrated app and CGM connectivity.
• Additional offerings: CareLink patient and clinician software, CareLink Clinic for clinic-level insights, MiniMed Mobile apps, and a portfolio of infusion sets, reservoirs, and other consumables.
• Pipeline: MiniMed Fit patch pump (extended wear), MiniMed Flex tubed pump (smaller form factor, smartphone control), and the next-generation Vivera dosing algorithm for a more hands-free user experience.

Market and customers

• Addressable market: people with Type 1 diabetes and insulin-requiring Type 2 diabetes, including insulin-dependent T2D patients in certain markets. Global market size exceeds $19 billion based on last-twelve-month revenue data from February 2026 across leading manufacturers.
• Global presence: operations in more than 80 countries.
• Installed base: over 640,000 pump users on MiniMed systems (references as of October 2025 and April 2026).
• Revenue geography: outside-the-United-States revenue represented about 70% of total revenue in fiscal 2026 and about 67% in fiscal 2025; the U.S. represented roughly 30% of revenue in 2026.

Scale and people

• Workforce: approximately 8,000 employees worldwide as of April 2026.
• Commercial and support: commercial workforce exceeds 2,800 employees; customer care and technology support include more than 1,300 staff across 24/7 multilingual centers.
• R&D: about 15% of the technical workforce is dedicated to innovation and research and development.

Financial highlights

• Revenue:
  • 2026: approximately $3.1 billion
  • 2025: approximately $2.7 billion
• Net income (loss):
  • 2026: net loss of about $317 million (about 10% of revenue)
  • 2025: net loss of about $198 million (about 7% of revenue)
• Adjusted EBITDA:
  • 2026: about $202 million (approximately 6% of revenue)
  • 2025: about $253 million (approximately 9% of revenue)
• Revenue mix: approximately 82% (2026) and 80% (2025) of revenue from CGMs, consumables, software, and services (non-device hardware revenue within the integrated system).
• Profitability and margin metrics are presented as non-GAAP Adjusted EBITDA alongside GAAP net income (loss).

Manufacturing and operations

• Manufacturing facilities: Northridge, California, and Juncos, Puerto Rico.
• Distribution hubs: Louisville, Kentucky, and Heerlen, Netherlands, plus 26 additional distribution facilities worldwide.
• Supply chain and quality: global supplier network and established quality and regulatory systems (ISO 13485, QSR, etc.).

Intellectual property and brand

• Patent portfolio: over 2,000 patents and patent applications worldwide (as of April 2026).
• Trademarks: over 350 registrations/applications worldwide (as of May 2026).
• Proprietary technologies across pumps, CGMs, dosing algorithms, software/apps, and accessories; uses a Virtual Patient Model with more than 430 million data points to accelerate algorithm development.

Key partnerships and strategic relationships

• Abbott integration and supply agreement: Abbott CGMs, including Instinct, are exclusive suppliers for certain AID/Smart MDI systems under a global agreement expanded in June 2026, with a seven-year term starting June 1, 2026 (auto-renewing). The agreement covers dual glucose-ketone sensors designed to integrate with MiniMed systems and includes performance-based launch conditions and purchasing restrictions.
• Blackstone co-development agreements: legacy Medtronic-era arrangements with Blackstone Life Sciences for development of certain diabetes products (e.g., MiniMed Flex, MiniMed Fit, previously MiniMed Duo). In 2025, two co-development agreements were mutually terminated with a one-time $165 million payment and release of ongoing obligations other than survival provisions. In 2026, the company recorded a one-time charge of $157 million related to minimum royalty obligations under Blackstone arrangements tied to MiniMed Flex’s FDA clearance and launch.

Competitive positioning and strategy

• Position: a global leader in insulin pumps by users, with an integrated ecosystem that combines hardware, sensors, algorithms, software, and services.
• Clinical evidence: maintains a strong real-world evidence base and meta-analyses reporting improved glycemic outcomes (Time in Range, TITR) versus competing systems and traditional MDI approaches.
• Growth priorities: expand AID adoption across the addressable market, increase CGM attachment (including Simplera Sync and Instinct), pursue broader labeling (including T2D indications), grow Smart MDI adoption with MiniMed Go, and accelerate next-generation products (MiniMed Fit, MiniMed Flex, Vivera dosing algorithm).
• Product strategy: broaden the addressable population with patch pumps and hands-free AID experiences, using a unified software platform and a single app across devices.

Regulatory and compliance

• Regulatory oversight: U.S. FDA (PMAs, 510(k)s) and EU MDR/CE marking processes, with ongoing post-market surveillance, labeling, and adverse event reporting requirements.
• Global compliance: engages with multiple regulatory regimes and payor systems to support market access in more than 80 countries; maintains quality systems and regulatory affairs capabilities.
• Data and legal compliance: obligations under HIPAA, GDPR/UK GDPR, CCPA, and other country-specific laws; compliance programs for anti-corruption, false claims acts, and other healthcare regulations.

Executive summary

MiniMed Group, Inc. operates as a vertically integrated diabetes technology company providing an end-to-end diabetes management platform: automated insulin delivery and Smart MDI hardware, CGMs and sensors, dosing algorithms and analytics, care-management software, and customer support. The company’s integrated hardware/software ecosystem, global manufacturing and distribution footprint, and pipeline of next-generation products support its strategy to make diabetes management more automated, simpler, and data-driven. Revenue growth has been driven by recent product launches, geographic expansion, and a growing installed base of pump users, supported by ongoing R&D investment and strategic partnerships.